The estimated Net Worth of Partners L P/Ilbiotechnolog... is at least $103 Milione dollars as of 21 May 2020. Partners Ilbiotechnolog owns over 2,283,598 units of XOMA Royalty stock worth over $13,029,316 and over the last 9 years Partners sold XOMA stock worth over $89,594,443.
Partners has made over 56 trades of the XOMA Royalty stock since 2016, according to the Form 4 filled with the SEC. Most recently Partners sold 2,283,598 units of XOMA stock worth $13,701,588 on 21 May 2020.
The largest trade Partners's ever made was buying 6,333,333 units of XOMA Royalty stock on 8 February 2018 worth over $18,999,999. On average, Partners trades about 678,164 units every 27 days since 2016. As of 21 May 2020 Partners still owns at least 480,432 units of XOMA Royalty stock.
You can see the complete history of Partners Ilbiotechnolog stock trades at the bottom of the page.
Over the last 21 years, insiders at XOMA Royalty have traded over $74,428,857 worth of XOMA Royalty stock and bought 6,217,869 units worth $44,091,555 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... e Bros. Advisors Lp667, L.P.B.... On average, XOMA Royalty executives and independent directors trade stock every 31 days with the average trade being worth of $3,397,377. The most recent stock trade was executed by Owen Hughes on 2 October 2023, trading 1,000 units of XOMA stock currently worth $13,830.
xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.
XOMA Royalty executives and other stock owners filed with the SEC include: